It’s Pharma Time: Why Merck and Lilly Are Buys, but Not Pfizer.


  • Order Reprints
  • Print Article

Michael Vi/

My 2023 biotech outlook calls for continued momentum in name changes. I just need to figure out what the stocks will do.

Last year, Respira Technologies became Qnovia. It’s run by a former tobacco executive with vape experience, and it’s developing an inhaled nicotine platform for quitting smoking. On one hand, I found years ago that a pretty good platform for that is just to not inhale any more nicotine. But on the other hand, going from Q straight to N in a company name sounds clinically promising.


Please enter your comment!
Please enter your name here